The pharmacology and mechanism of action of riluzole

Neurology

Volumn 47, Issue 6 SUPPL. 4, 1996, Pages

  Doble, A ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; CARBAMAZEPINE; DIAZEPAM; DIZOCILPINE; EXCITOTOXIN; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PERTUSSIS TOXIN; RILUZOLE; SODIUM CHANNEL; VERATRIDINE;

AMYOTROPHIC LATERAL SCLEROSIS; ANTICONVULSANT ACTIVITY; BRAIN ISCHEMIA; CEREBROSPINAL FLUID; DRUG MECHANISM; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LOCAL ANESTHESIA; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SEDATION;

EID: 0029753270     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.47.6_suppl_4.233s     Document Type: Review

References (30)

1. Watkins JC, Evans RH. Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol 1981;21:165-204.
2. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990;11:379-387.
3. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. New Engl J Med 1994;330:613-622.
4. Louvel E, Hugon J, Doble A. Advances in amyotrophic lateral sclerosis. Trends Pharmacol Sci 1996 (in press).
5. Leigh PN, Meldrum BS. Excitotoxicity in ALS. Neurology 1996;47(suppl 4):S221-S227.
6. Mizoule J, Meldrum B, Mazadier M, et al. 2-amino-6-trifluoromethoxybenzothiazole, a possible antagonist of excitatory amino acid neurotransmission. I. Anticonvulsant properties. Neuropharmacology 1985;24:767-773.
7. Benavides J, Camelin JC, Mitrani N, et al. 2-amino-6-trifluoromethoxybenzothiazole, a possible antagonist of excitatory amino acid neurotransmission. II. Biochemical properties. Neuropharmacology 1985;24:1085-1092.
8. 3H]-aspartate release from cultured cerebellar granule cells. Neurosci Lett 1989;96:345-350.
9. Barbeito L, Cheramy A, Godeheu G, et al. Glutamate receptors of a quisqualate-kainate subtype are involved in the presynaptic regulation of dopamine release in the cat caudate nucleus in vivo. Eur J Neurosci 1990;2:304-311.
10. Debono MW, Le Guern J, Canton T, et al. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 1993;235:283-289.
11. Hubert JP, Delumeau JC, Glowinski J, et al. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Br J Pharmacol 1994;113:261-267.
12. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993; 250:473-476.
13. Cheramy A, Barbeito L, Godeheu G, Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 1992;147:209-212.
14. 3H]-aspartate release from cerebellar granule cells. Neurosci Lett 1992;140:251-254.
15. Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibres. Pflügers Arch 1991; 419:603-609.
16. Hebert T, Drapeau P, Pradier L, Dunn RJ. Block of the rat brain IIA sodium channel α subunit by the neuroprotective drug riluzole. Mol Pharmacol 1994;45:1055-1060.
17. Malgouris C, Daniel M, Doble A. Neuroprotective effects of riluzole on N-methyl-D-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices. Eur J Pharmacol 1994; 177;95-99.
18. Estevez AG, Stutzmann JM, Barbeito L. Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures. Eur J Pharmacol 1995;280:47-53.
19. Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neurone toxicity. J Neurochem 1995;65:643-651.
20. Dessi F, Ben-Ari Y, Charriaut-Marlangue C. Riluzole prevents anoxic injury in cultured cerebellar granule neurones. Eur J Pharmacol 1993;250:325-328.
21. Couratier P, Hugon J, Sindou P, et al. Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors. Lancet 1993;341:268-270.
22. Couratier P, Sindou P, Esclaire F, et al. Neuroprotective effects of riluzole in ALS CSF toxicity. Neuroreport 1994;5: 1012-1014.
23. Pratt J, Rataud J, Bardot F, et al. Neuroprotective actions of riluzole in rodent models of global and focal ischaemia. Neurosci Lett 1992;140:225-230.
24. Wahl F, Allix M, Plotkine M, Boulu RG. Effect of riluzole on focal cerebral ischaemia in rats. Eur J Pharmacol 1993;230: 209-214.
25. Malgouris C, Bardot F, Daniel M, et al. Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischaemic gerbils. J Neurosci 1989;9:3720-3727.
26. Boireau A, Dubedat P, Bordier F, et al. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport 1994;5:2657-2660.
27. +-induced increase in striatal extracellular dopamine in rats in vivo. Neuroreport 1994;5:2157-2160.
28. Benazzouz A, Boraud A, Dubedat P, et al. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 1995;284:299-307.
29. Barnéoud P, Mazadier M, Miquet JM, et al. Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience 1996 (in press).
30. Boireau A, Bordier F, Dubedat P, Doble A. Methamphetamine and dopaminergic neurotoxicity: differential effects of agents interfering with glutamatergic transmission. Neurosci Lett 1995;195:9-12.